HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol

Exclusion Criteria

• •Concurrent Medication:
• •Excluded:
• •Ongoing therapy for CMV disease with ganciclovir, foscarnet, CMV hyperimmune immunoglobulin, or other investigational agents with anti-CMV activity.
• •Therapy with nephrotoxic drugs, including amphotericin B, aminoglycoside antibiotics, vidarabine, and intravenous pentamidine.
• •Patients with the following prior conditions are excluded:
• •History of renal disease or renal dialysis.
• •History of clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia.
• •History of clinically significant probenecid allergy.
• •Prior Medication:
• •Excluded:
• •Prior therapy for CMV disease with ganciclovir, foscarnet, CMV hyperimmune immunoglobulin, or other investigational agents with anti-CMV activity.
• •Therapy with nephrotoxic drugs within the past 7 days, including amphotericin B, aminoglycoside antibiotics, vidarabine, and intravenous pentamidine.
• •Drug or alcohol abuse sufficient to hinder compliance with study.